-
Amgen Inc. et al v. Hospira, Inc. DC CAFC
- 1:15-cv-00839
- D. Del.
- Filed: 09/18/2015
- Closed: 09/11/2018
- Latest Docket Entry: 09/24/2020
- Judge: Richard G. Andrews
- PACER
2
Plaintiffs
1
Defendant
1
Accused
Product
2
Patents-in-Suit
1,090
Days in
Litigation
-
Amgen Inc. et al v. Hospira, Inc. DC CAFC
- 1:15-cv-00839
- D. Del.
- Filed: 09/18/2015
- Closed: 09/11/2018
- Latest Docket Entry: 09/24/2020
- Judge: Richard G. Andrews
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 8 |
A composition consisting essentially of two or three erythropoietin isoforms according to claim 1.
|
Invalid
Entry 393 |
| 19 |
A composition consisting essentially of erythropoietin molecules according to claim 13 having two or three specific numbers of sialic acids per erythropoietin molecule.
|
Invalid
Entry 393 |
| 24 |
A method of preparing erythropoietin molecules having a predetermined number of sialic acids per molecule said number selected from the group consisting of 1-14, comprising applying material containing erythropoietin to an ion exchange column and
view more
|
Valid (102 and 103)
Entry 393 Entry 326 |
| 27 |
A method for obtaining an erythropoietin composition having a predetermined in vivo specific activity comprising preparing a mixture of two or more erythropoietin isoforms of claim 1.
|
Valid (102 and 103)
Entry 393 Entry 326 |
-
Infringement
Hospira Incorporated
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| Epoetin biosimilar product | US 5,756,349 A |
1, 2, 3, 4, 5, 6, 7
|
No infringement
Entry 393Entry 326 |
| Epoetin biosimilar product | US 5,856,298 A |
24, 27
|
Infringement
Entry 326
|
-
Damages